June 23rd, 2016
Leading US gastrointestinal cancer expert, Professor Margaret Tempero appointed to Immunovia’s Scientific Advisory Board
LUND, Sweden ― As Immunovia maintains progress towards delivering the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Margaret Tempero has been appointed to the company’s Scientific Advisory Board. Currently, Professor Tempero is Director of the UCSF Pancreas Center and leader of the Pancreas Cancer Program at the UCSF.
Professor Tempero is a professor of medicine in Hematology and Oncology and a pioneer in applying radioactively tagged antibodies for cancer therapy and is leading national US research projects for gastrointestinal cancer, including pancreatic cancer. She has served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000, is Co-chair on the Pancreas Task Force Tissue Acquisition Working Group for the NCI intergroup and co-organized the State of the Science meeting on pancreatic cancer at the NCI. Professor Tempero has also held many appointments at AACR and ASCO and served as a member of the ASCO Board of Directors and as ASCO President in 2004. She was a member of the Oncology Drug Advisory Committee for the FDA from 2007-2011. Professor Tempero is or has been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC.
“Professor Tempero brings immense experience to our Scientific Board and we are delighted she has agreed to join. Her perspective and network will be invaluable as we look to extend our trial programs into key US centers and further our discussions with the FDA,” said Mats Grahn, CEO, Immunovia.
Professor Tempero added: “I am pleased to join Immunovia’s Scientific Advisory Board at this exciting stage of the company’s development. If successful, I believe IMMray™ PanCan-d can make a real difference in improving pancreatic cancer diagnosis and treatment and increasing patient survival rates.”
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
About Pancreatic Cancer
Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 4-6%. It is predicted to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, can significantly improve pancreatic cancer patients’ 5-year survival rates from 4-6% to potentially 50-60%.